BioCryst Pharmaceuticals, Inc.
Prodrugs of kallikrein inhibitors
Last updated:
Abstract:
Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
27 Oct 2017
Issue date:
1 Sep 2020